David L Narum

List of Publications by Year
in descending order

118 papers	6,591 citations	61984 43 h-index	71685 76 g-index
125 all docs	125 docs citations	125 times ranked	5071 citing authors

#	Article	IF	Citations
1	Effect of 4 years of seasonal malaria chemoprevention on the acquisition of antibodies to Plasmodium falciparum antigens in Ouelessebougou, Mali. Malaria Journal, 2021, 20, 23.	2.3	3
2	A human monoclonal antibody blocks malaria transmission and defines a highly conserved neutralizing epitope on gametes. Nature Communications, 2021, 12, 1750.	12.8	39
3	Pfs230 yields higher malaria transmissionâ€“blocking vaccine activity than Pfs25 in humans but not mice. Journal of Clinical Investigation, 2021, 131, .	8.2	49
4	An invariant protein that co-localizes with VAR2CSA on Plasmodium falciparum-infected red cells binds to chondroitin sulfate A. Journal of Infectious Diseases, 2021, , .	4.0	3
5	Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques. Npj Vaccines, 2021, 6, 148.	6.0	14
6	Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins. Communications Biology, 2020, 3, 395.	4.4	37
7	Bliss' and Loewe's additive and synergistic effects in Plasmodium falciparum growth inhibition by AMA1-RON2L, RH5, RIPR and CyRPA antibody combinations. Scientific Reports, 2020, 10, 11802.	3.3	18
8	Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230. Vaccine, 2020, 38, 5480-5489.	3.8	15
9	Antimalarial antibody repertoire defined by plasma IG proteomics and single B cell IG sequencing. JCI Insight, 2020, 5, .	5.0	12
10	Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230. Npj Vaccines, 2019, 4, 24.	6.0	35
11	Host cell protein quantification of an optimized purification method by mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2019, 174, 650-654.	2.8	8
12	Naturally Acquired Antibody Response to Malaria Transmission Blocking Vaccine Candidate Pvs230 Domain 1. Frontiers in Immunology, 2019, 10, 2295.	4.8	6
13	Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/AlhydrogelÂ® in mice. Vaccine, 2019, 37, 1038-1045.	3.8	8
14	Intermittent screening and treatment with dihydroartemisinin-piperaquine and intermittent preventive therapy with sulfadoxine-pyrimethamine have similar effects on malaria antibody in pregnant Malawian women. Scientific Reports, 2019, 9, 7878.	3.3	2
15	Functional Antibodies against Placental Malaria Parasites Are Variant Dependent and Differ by Geographic Region. Infection and Immunity, 2019, 87, .	2.2	16
16	Assessment of the impact of manufacturing changes on the physicochemical properties of the recombinant vaccine carrier ExoProtein A. Vaccine, 2019, 37, 5762-5769.	3.8	13
17	Antibody levels to recombinant VAR2CSA domains vary with Plasmodium falciparum parasitaemia, gestational age, and gravidity, but do not predict pregnancy outcomes. Malaria Journal, 2018, 17, 106.	2.3	24
18	NK cells inhibit Plasmodium falciparum growth in red blood cells via antibody-dependent cellular cytotoxicity. ELife, 2018, 7, .	6.0	92

#	Article	IF	Citations
19	Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults. Lancet Infectious Diseases, The, 2018, 18, 969-982.	9.1	101
20	Antibody targeting of a specific region of Pfs47 blocks Plasmodium falciparum malaria transmission. Npj Vaccines, 2018, 3, 26.	6.0	54
21	TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25. JCI Insight, 2018, 3, .	5.0	59
22	Protein-Specific Features Associated with Variability in Human Antibody Responses to Plasmodium falciparum Malaria Antigens. American Journal of Tropical Medicine and Hygiene, 2018, 98, 57-66.	1.4	10
23	Decrease in Numbers of Naive and Resting B Cells in HIV-Infected Kenyan Adults Leads to a Proportional Increase in Total and Plasmodium falciparumâ€“Specific Atypical Memory B Cells. Journal of Immunology, 2017, 198, 4629-4638.	0.8	13
24	A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection. Npj Vaccines, 2017, 2, .	6.0	52
25	Profiling invasive Plasmodium falciparum merozoites using an integrated omics approach. Scientific Reports, 2017, 7, 17146.	3.3	9
26	Sero-catalytic and Antibody Acquisition Models to Estimate Differing Malaria Transmission Intensities in Western Kenya. Scientific Reports, 2017, 7, 16821.	3.3	15
27	Differing rates of antibody acquisition to merozoite antigens in malaria: implications for immunity and surveillance. Journal of Leukocyte Biology, 2017, 101, 913-925.	3.3	41
28	Effect of seasonal malaria chemoprevention on the acquisition of antibodies to Plasmodium falciparum antigens in Ouelessebougou, Mali. Malaria Journal, 2017, 16, 289.	2.3	12
29	Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with AlhydrogelÂ®. Vaccine, 2017, 35, 3232-3238.	3.8	2
30	Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity. PLoS ONE, 2017, 12, e0190312.	2.5	37
31	VAR2CSA Domain-Specific Analysis of Naturally Acquired Functional Antibodies toPlasmodium falciparumPlacental Malaria. Journal of Infectious Diseases, 2016, 214, 577-586.	4.0	35
32	Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230. Journal of Biological Chemistry, 2016, 291, 19913-19922.	3.4	91
33	The Regulation of Inherently Autoreactive VH4-34â€“Expressing B Cells in Individuals Living in a Malaria-Endemic Area of West Africa. Journal of Immunology, 2016, 197, 3841-3849.	0.8	15
34	Maternal-foetal transfer of Plasmodium falciparum and Plasmodium vivax antibodies in a low transmission setting. Scientific Reports, 2016, 6, 20859.	3.3	13
35	Contrasting Patterns of Serologic and Functional Antibody Dynamics to Plasmodium falciparum Antigens in a Kenyan Birth Cohort. Vaccine Journal, 2016, 23, 104-116.	3.1	24
36	A Method for Producing Protein Nanoparticles with Applications in Vaccines. PLoS ONE, 2016, 11, e0138761.	2.5	20

#	Article	IF	Citations
37	Safety and Immunogenicity of Pfs25-EPA/AlhydrogelÂ®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria NaÃ¯ve Adults. PLoS ONE, 2016, 11, e0163144.	2.5	114
38	Identification of an Immunogenic Mimic of a Conserved Epitope on the Plasmodium falciparum Blood Stage Antigen AMA1 Using Virus-Like Particle (VLP) Peptide Display. PLoS ONE, 2015, 10, e0132560.	2.5	15
39	Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains. Infection and Immunity, 2015, 83, 3771-3780.	2.2	59
40	Particle-based platforms for malaria vaccines. Vaccine, 2015, 33, 7518-7524.	3.8	28
41	Simplagrin, a Platelet Aggregation Inhibitor from Simulium nigrimanum Salivary Glands Specifically Binds to the Von Willebrand Factor Receptor in Collagen and Inhibits Carotid Thrombus Formation In Vivo. PLoS Neglected Tropical Diseases, 2014, 8, e2947.	3.0	12
42	Estimation of Recent and Long-Term Malaria Transmission in a Population by Antibody Testing to Multiple Plasmodium falciparum Antigens. Journal of Infectious Diseases, 2014, 210, 1123-1132.	4.0	58
43	Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10311-10316.	7.1	92
44	NOS2 Variants Reveal a Dual Genetic Control of Nitric Oxide Levels, Susceptibility to Plasmodium Infection, and Cerebral Malaria. Infection and Immunity, 2014, 82, 1287-1295.	2.2	23
45	Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle. Vaccine, 2013, 31, 2954-2962.	3.8	97
46	Disrupting malaria parasite AMA1â€“RON2 interaction with a small molecule prevents erythrocyte invasion. Nature Communications, 2013, 4, 2261.	12.8	87
47	Determination of protein concentration for proteinâ€“protein conjugates using ultraviolet absorption. Journal of Immunological Methods, 2013, 387, 317-321.	1.4	7
48	Overcoming Allelic Specificity by Immunization with Five Allelic Forms of Plasmodium falciparum Apical Membrane Antigen 1. Infection and Immunity, 2013, 81, 1491-1501.	2.2	40
49	Multilaboratory Approach to Preclinical Evaluation of Vaccine Immunogens for Placental Malaria. Infection and Immunity, 2013, 81, 487-495.	2.2	36
50	Identification of VAR2CSA Domain-Specific Inhibitory Antibodies of the Plasmodium falciparum Erythrocyte Membrane Protein 1 Using a Novel Flow Cytometry Assay. Vaccine Journal, 2013, 20, 433-442.	3.1	24
51	Identification and Prioritization of Merozoite Antigens as Targets of Protective Human Immunity to Plasmodium falciparum Malaria for Vaccine and Biomarker Development. Journal of Immunology, 2013, 191, 795-809.	0.8	213
52	The Epitope of Monoclonal Antibodies Blocking Erythrocyte Invasion by Plasmodium falciparum Map to The Dimerization and Receptor Glycan Binding Sites of EBA-175. PLoS ONE, 2013, 8, e56326.	2.5	31
53	Structural and Immunological Analysis of Anthrax Recombinant Protective Antigen Adsorbed to Aluminum Hydroxide Adjuvant. Vaccine Journal, 2012, 19, 1465-1473.	3.1	42
54	Analysis of the Conformation and Function of the Plasmodium falciparum Merozoite Proteins MTRAP and PTRAMP. Eukaryotic Cell, 2012, 11, 615-625.	3.4	28

#	Article	IF	Citations
55	Plasmodium falciparum merozoite surface protein 1 blocks the proinflammatory protein S100P. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5429-5434.	7.1	20
56	New Insights into Acquisition, Boosting, and Longevity of Immunity to Malaria in Pregnant Women. Journal of Infectious Diseases, 2012, 206, 1612-1621.	4.0	85
57	Binding of Aldolase and Glyceraldehyde-3-Phosphate Dehydrogenase to the Cytoplasmic Tails of Plasmodium falciparum Merozoite Duffy Binding-Like and Reticulocyte Homology Ligands. MBio, 2012, 3, .	4.1	16
58	Malaria infection alters the expression of <scp>B</scp>â€cell activating factor resulting in diminished memory antibody responses and survival. European Journal of Immunology, 2012, 42, 3291-3301.	2.9	38
59	Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer. Vaccine, 2012, 30, 189-194.	3.8	20
60	Broadly reactive antibodies specific for Plasmodium falciparum MSP-119 are associated with the protection of naturally exposed children against infection. Malaria Journal, 2012, 11, 287.	2.3	9
61	Immunogenicity of Self-Associated Aggregates and Chemically Cross-Linked Conjugates of the 42 kDa Plasmodium falciparum Merozoite Surface Protein-1. PLoS ONE, 2012, 7, e36996.	2.5	17
62	Phase 1 Study in Malaria NaÃ¯ve Adults of BSAM2/AlhydrogelÂ®+CPG 7909, a Blood Stage Vaccine against P. falciparum Malaria. PLoS ONE, 2012, 7, e46094.	2.5	50
63	Delineation of Stage Specific Expression of Plasmodium falciparum EBA-175 by Biologically Functional Region II Monoclonal Antibodies. PLoS ONE, 2011, 6, e18393.	2.5	34
64	Antibodies to Plasmodium falciparum Erythrocyte-binding Antigen-175 are Associated With Protection From Clinical Malaria. Pediatric Infectious Disease Journal, 2011, 30, 1037-1042.	2.0	29
65	Antibodies to Plasmodium falciparum Antigens Predict a Higher Risk of Malaria But Protection From Symptoms Once Parasitemic. Journal of Infectious Diseases, 2011, 204, 19-26.	4.0	89
66	Malaria infection by sporozoite challenge induces high functional antibody titres against blood stage antigens after a DNA prime, poxvirus boost vaccination strategy in Rhesus macaques. Malaria Journal, 2011, 10, 29.	2.3	13
67	Binding of Plasmodium merozoite proteins RON2 and AMA1 triggers commitment to invasion. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13275-13280.	7.1	253
68	Aegyptin displays highâ€affinity for the von Willebrand factor binding site (RGQOGVMGF) in collagen and inhibits carotid thrombus formation inâ€vivo. FEBS Journal, 2010, 277, 413-427.	4.7	42
69	Association between Naturally Acquired Antibodies to Erythrocyteâ€Binding Antigens of Plasmodium falciparum and Protection from Malaria and Highâ€Density Parasitemia. Clinical Infectious Diseases, 2010, 51, e50-e60.	5.8	184
70	Immunization with VAR2CSA-DBL5 Recombinant Protein Elicits Broadly Cross-Reactive Antibodies to Placental Plasmodium falciparum -Infected Erythrocytes. Infection and Immunity, 2010, 78, 2248-2256.	2.2	34
71	A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6958-6963.	7.1	412
72	The Plasmodium falciparum-Specific Human Memory B Cell Compartment Expands Gradually with Repeated Malaria Infections. PLoS Pathogens, 2010, 6, e1000912.	4.7	221

#	Article	IF	Citations
73	Phase 1 Trial of the Plasmodium falciparum Blood Stage Vaccine MSP142-C1/Alhydrogel with and without CPG 7909 in Malaria NaÃ¯ve Adults. PLoS ONE, 2010, 5, e8787.	2.5	76
74	Malaria Vaccine Development. , 2010, , 409-422.		0
75	Structure of the Plasmodium falciparum Circumsporozoite Protein, a Leading Malaria Vaccine Candidate. Journal of Biological Chemistry, 2009, 284, 26951-26963.	3.4	132
76	Can Prenatal Malaria Exposure Produce an Immune Tolerant Phenotype?: A Prospective Birth Cohort Study in Kenya. PLoS Medicine, 2009, 6, e1000116.	8.4	131
77	Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure. Molecular and Biochemical Parasitology, 2009, 164, 45-56.	1.1	19
78	Enhanced antibody responses to Plasmodium falciparum Pfs28 induced in mice by conjugation to ExoProtein A of Pseudomonas aeruginosa with an improved procedure. Microbes and Infection, 2009, 11, 408-412.	1.9	30
79	Optimizing expression of the pregnancy malaria vaccine candidate, VAR2CSA in Pichia pastoris. Malaria Journal, 2009, 8, 143.	2.3	18
80	The TLR9 Ligand CpG Promotes the Acquisition of Plasmodium falciparum-Specific Memory B Cells in Malaria-Naive Individuals. Journal of Immunology, 2009, 182, 3318-3326.	0.8	73
81	Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders. Vaccine, 2008, 26, 2521-2527.	3.8	29
82	Evidence for Globally Shared, Cross-Reacting Polymorphic Epitopes in the Pregnancy-Associated Malaria Vaccine Candidate VAR2CSA. Infection and Immunity, 2008, 76, 1791-1800.	2.2	47
83	Ex Vivo Cytokine and Memory T Cell Responses to the 42-kDa Fragment ofPlasmodium falciparumMerozoite Surface Protein-1 in Vaccinated Volunteers. Journal of Immunology, 2008, 180, 1451-1461.	0.8	33
84	Low Prevalence of Antibodies to Preerythrocytic but Not Blood-StagePlasmodium falciparumAntigens in an Area of Unstable Malaria Transmission Compared to Prevalence in an Area of Stable Malaria Transmission. Infection and Immunity, 2008, 76, 5721-5728.	2.2	39
85	Identification and Characterization of the Plasmodium yoelii PyP140/RON4 Protein, an Orthologue of Toxoplasma gondii RON4, Whose Cysteine-Rich Domain Does Not Protect against Lethal Parasite Challenge Infection. Infection and Immunity, 2008, 76, 4876-4882.	2.2	32
86	Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51. PLoS ONE, 2008, 3, e2636.	2.5	347
87	Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 293-298.	7.1	83
88	Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: A strategy for enhancing immunogenicity of malaria vaccine candidates. Vaccine, 2007, 25, 3923-3933.	3.8	69
89	Phase 1 Study of Two Merozoite Surface Protein 1 (MSP142) Vaccines for Plasmodium falciparum Malaria. PLOS Clinical Trials, 2007, 2, e12.	3.5	71
90	Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P. pastoris. Journal of Biotechnology, 2006, 121, 458-470.	3.8	83

#	Article	IF	Citations
91	Production and characterization of clinical grade Escherichia coli derived Plasmodium falciparum 42kDa merozoite surface protein 1 (MSP142) in the absence of an affinity tag. Protein Expression and Purification, 2006, 50, 58-67.	1.3	29
92	Screen-less expanded bed column: new approach for the recovery and purification of a malaria transmission blocking vaccine candidate from Pichia pastoris. Biotechnology Letters, 2006, 28, 951-958.	2.2	3
93	Passive Immunization with a Multicomponent Vaccine against Conserved Domains of Apical Membrane Antigen 1 and 235-Kilodalton Rhoptry Proteins Protects Mice against Plasmodium yoelii Blood-Stage Challenge Infection. Infection and Immunity, 2006, 74, 5529-5536.	2.2	27
94	Antibodies to Plasmodium falciparum Antigens Vary by Age and Antigen in Children in a Malaria-Holoendemic Area of Kenya. Pediatric Infectious Disease Journal, 2005, 24, 680-684.	2.0	26
95	CORRELATION OF HIGH LEVELS OF ANTIBODIES TO MULTIPLE PRE-ERYTHROCYTIC PLASMODIUM FALCIPARUM ANTIGENS AND PROTECTION FROM INFECTION. American Journal of Tropical Medicine and Hygiene, 2005, 73, 222-228.	1.4	104
96	Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. American Journal of Tropical Medicine and Hygiene, 2005, 73, 222-8.	1.4	82
97	Reduced immunogenicity of DNA vaccine plasmids in mixtures. Gene Therapy, 2004, 11, 448-456.	4.5	76
98	Characterisation of the rhoph2 gene of Plasmodium falciparum and Plasmodium yoelii. Molecular and Biochemical Parasitology, 2003, 127, 47-57.	1.1	43
99	Absence of antigenic competition in Aotus monkeys immunized with Plasmodium falciparum DNA vaccines delivered as a mixture. Vaccine, 2002, 20, 1675-1680.	3.8	30
100	A novel Plasmodium falciparum erythrocyte binding protein-2 (EBP2/BAEBL) involved in erythrocyte receptor binding. Molecular and Biochemical Parasitology, 2002, 119, 159-168.	1.1	65
101	Induction of Biologically Active Antibodies in Mice, Rabbits, and Monkeys by Plasmodium falciparum EBA-175 Region II DNA vaccine. Molecular Medicine, 2001, 7, 247-254.	4.4	31
102	Sequence diversity and antigenic polymorphism in the Plasmodium yoelii p235 high molecular mass rhoptry proteins and their genes. Molecular and Biochemical Parasitology, 2001, 112, 193-200.	1.1	11
103	Erythrocyte-binding activity of Plasmodium yoelii apical membrane antigen-1 expressed on the surface of transfected COS-7 cells. Molecular and Biochemical Parasitology, 2001, 117, 49-59.	1.1	70
104	Endostatin Binds Tropomyosin. Journal of Biological Chemistry, 2001, 276, 25190-25196.	3.4	108
105	Codon Optimization of Gene Fragments Encoding Plasmodium falciparum Merzoite Proteins Enhances DNA Vaccine Protein Expression and Immunogenicity in Mice. Infection and Immunity, 2001, 69, 7250-7253.	2.2	110
106	Molecular characterisation of Plasmodium reichenowi apical membrane antigen-1 (AMA-1), comparison with P. falciparum AMA-1, and antibody-mediated inhibition of red cell invasion. Molecular and Biochemical Parasitology, 2000, 109, 147-156.	1.1	75
107	Plasmodium yoelii: Effects of Red Blood Cell Modification and Antibodies on the Binding Characteristics of the 235-kDa Rhoptry Protein. Experimental Parasitology, 2000, 95, 187-195.	1.2	29
108	Antibodies against the Plasmodium falciparum Receptor Binding Domain of EBA-175 Block Invasion Pathways That Do Not Involve Sialic Acids. Infection and Immunity, 2000, 68, 1964-1966.	2.2	82

#	Article	IF	Citations
109	Immunization with Parasite-Derived Apical Membrane Antigen 1 or Passive Immunization with a Specific Monoclonal Antibody Protects BALB/c Mice against Lethal Plasmodium yoelii yoelii YM Blood-Stage Infection. Infection and Immunity, 2000, 68, 2899-2906.	2.2	103
110	A Recombinant Baculovirus-Expressed Plasmodium falciparum Receptor-Binding Domain of Erythrocyte Binding Protein EBA-175 Biologically Mimics Native Protein. Infection and Immunity, 2000, 68, 3564-3568.	2.2	35
111	Analysis of the processing of Plasmodium falciparum rhoptry-associated protein 1 and localization of Pr86 to schizont rhoptries and p67 to free merozoites. Molecular and Biochemical Parasitology, 1998, 92, 111-122.	1.1	40
112	Precise Timing of Expression of a Plasmodium falciparum- derived Transgene in Plasmodium berghei Is a Critical Determinant of Subsequent Subcellular Localization. Journal of Biological Chemistry, 1998, 273, 15119-15124.	3.4	150
113	Immunization of Aotus Monkeys with Recombinant Plasmodium falciparum Hybrid Proteins Does Not Reproducibly Result in Protection from Malaria Infection. Infection and Immunity, 1998, 66, 373-375.	2.2	8
114	Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Molecular and Biochemical Parasitology, 1994, 67, 59-68.	1.1	244
115	High Prevalence of Natural Antibodies against Plasmodium falciparum 83-Kilodalton Apical Membrane Antigen (PF83/AMA-1) as Detected by Capture-Enzyme-Linked Immunosorbent Assay Using Full-Length Baculovirus Recombinant PF83/AMA-1. American Journal of Tropical Medicine and Hygiene, 1994, 51, 730-740.	1.4	78
116	Ion-exchangeâ€"immunoaffinity purification of a recombinant baculovirus Plasmodium falciparum apical membrane antigen, PF83/AMA-1. Journal of Chromatography A, 1993, 657, 357-363.	3.7	17
117	Plasmodium berghei Ookinete Densities in Three Anopheline Species. Journal of Parasitology, 1991, 77, 758.	0.7	21
118	Natural history of malaria infections during early childhood in twins. Journal of Infectious Diseases, 0, , .	4.0	1